Amada, Naoki, et al. “Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression.” PeerJ 1 (2013): e214.
Appendino, Giovanni, et al. “Antibacterial cannabinoids from Cannabis sativa: a structure− activity study.” Journal of natural products 71.8 (2008): 1427-1430.
Bolognini, D., et al. “Cannabidiolic acid prevents vomiting in Suncus murinus and nausea‐induced behaviour in rats by enhancing 5‐HT1A receptor activation.” British journal of pharmacology 168.6 (2013): 1456-1470.
Bouchard, Maryse F., et al. “Attention-deficit/hyperactivity disorder and urinary metabolites of organophosphate pesticides.” Pediatrics 125.6 (2010): e1270-e1277.
Elsohly, Mahmoud A., et al. “Rectal bioavailability of Δ‐9‐tetrahydrocannabinol from the hemisuccinate ester in monkeys.” Journal of pharmaceutical sciences 80.10 (1991): 942-945.
Englund, Amir, et al. “The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.” Journal of Psychopharmacology (2015): 0269881115615104.)
Formukong, E., Analgesic and anti-inflammatory activity of constituents of Cannabis sativa L. Inflammation (1988) 12: 361
Garry, Vincent F., et al. “Pesticide appliers, biocides, and birth defects in rural Minnesota.” Environmental Health Perspectives 104.4 (1996): 394.
Gieringer, D., The California/MAPS Smoking Device Study, MAPS Newsletter 1996; www.canorml.org/healthfacts/smokestudy.html
Giacoppo, Sabrina, et al. “Cannabinoids: new promising agents in the treatment of neurological diseases.” Molecules 19.11 (2014): 18781-18816.
Hammell, D. C., et al. “Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis.” European Journal of Pain (2015).
Hayden, Kathleen M., et al. “Occupational exposure to pesticides increases the risk of incident AD The Cache County Study.” Neurology 74.19 (2010): 1524-1530.
Hill, A. J., et al. “Cannabidivarin is anticonvulsant in mouse and rat.” British journal of pharmacology 167.8 (2012): 1629-1642.
Hill, T. D. M., et al. “Cannabidivarin‐rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor‐independent mechanism.” British journal of pharmacology 170.3 (2013): 679-692.
Iannotti, Fabio Arturo, et al. “Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), activate and desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.” ACS chemical neuroscience 5.11 (2014): 1131-1141.
Izzo, Angelo A., et al. “Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.” Trends in pharmacological sciences 30.10 (2009): 515-527.
Karsak, M., “Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System.” Science (2007) 316: 1494-97
Laprairie, R. B., et al. "Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor." British journal of pharmacology 172.20 (2015): 4790-4805.
Mattes, Richard D., et al. “Bypassing the first-pass effect for the therapeutic use of cannabinoids.” Pharmacology Biochemistry and Behavior 44.3 (1993): 745-747.
Perlin, Elliott, et al. “Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey.” Journal of pharmaceutical sciences 74.2 (1985): 171-174.
Phan, Ngoc Quan, et al. “Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia.” JDDG: Journal der Deutschen Dermatologischen Gesellschaft 8.2 (2010): 88-91.
Rock, E. M., and L. A. Parker. “Effect of low doses of cannabidiolic acid and ondansetron on LiCl‐induced conditioned gaping (a model of nausea‐induced behaviour) in rats.” British journal of pharmacology 169.3 (2013): 685-692.
Russo, Ethan B. “Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects.” British journal of pharmacology 163.7 (2011): 1344-1364.
Russo, Ethan B. "Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues." Front Pharmacol (2016c) 7:309. doi: 10.3389/fphar.2016.00309.
Takeda, Shuso, et al. “Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis.” Drug metabolism and disposition 36.9 (2008): 1917-1921.
Takeda, Shuso, et al. “Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.” Toxicology letters 214.3 (2012): 314-319.
Zuardi, A., et al. “A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.” Curr Pharm Des 18.32 (2012): 5131-40.